Railway Pension Investments Ltd Buys 400 Shares of Johnson & Johnson (NYSE:JNJ)

Railway Pension Investments Ltd raised its stake in shares of Johnson & Johnson (NYSE:JNJ) by 0.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 826,336 shares of the company’s stock after acquiring an additional 400 shares during the quarter. Johnson & Johnson makes up about 1.3% of Railway Pension Investments Ltd’s portfolio, making the stock its 22nd biggest position. Railway Pension Investments Ltd’s holdings in Johnson & Johnson were worth $130,718,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. 4J Wealth Management LLC boosted its position in Johnson & Johnson by 2.2% during the fourth quarter. 4J Wealth Management LLC now owns 2,835 shares of the company’s stock worth $444,000 after acquiring an additional 62 shares during the last quarter. My Personal CFO LLC boosted its position in Johnson & Johnson by 1.4% during the fourth quarter. My Personal CFO LLC now owns 4,550 shares of the company’s stock worth $713,000 after acquiring an additional 62 shares during the last quarter. Eagle Strategies LLC raised its stake in Johnson & Johnson by 1.8% during the fourth quarter. Eagle Strategies LLC now owns 3,589 shares of the company’s stock worth $563,000 after purchasing an additional 63 shares during the period. Alliance Wealth Advisors LLC UT raised its stake in Johnson & Johnson by 1.4% during the fourth quarter. Alliance Wealth Advisors LLC UT now owns 4,714 shares of the company’s stock worth $739,000 after purchasing an additional 64 shares during the period. Finally, Carolinas Wealth Consulting LLC raised its stake in Johnson & Johnson by 0.4% during the fourth quarter. Carolinas Wealth Consulting LLC now owns 16,861 shares of the company’s stock worth $2,643,000 after purchasing an additional 64 shares during the period. Institutional investors own 69.55% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. Royal Bank of Canada reissued an “outperform” rating and issued a $175.00 target price on shares of Johnson & Johnson in a research note on Tuesday. Morgan Stanley lifted their price target on shares of Johnson & Johnson from $167.00 to $169.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 18th. Bank of America dropped their price target on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 17th. Daiwa Capital Markets downgraded shares of Johnson & Johnson from an “outperform” rating to a “neutral” rating and dropped their price target for the stock from $160.00 to $150.00 in a research note on Tuesday, July 23rd. Finally, HSBC raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and raised their price objective for the stock from $169.00 to $170.00 in a report on Thursday, April 18th. Eight research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $173.00.

Johnson & Johnson Stock Performance

Johnson & Johnson stock traded up $3.38 during midday trading on Friday, reaching $164.14. 11,280,357 shares of the stock traded hands, compared to its average volume of 7,234,699. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $175.97. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.44. The firm has a market cap of $395.12 billion, a price-to-earnings ratio of 10.23, a PEG ratio of 2.63 and a beta of 0.52. The firm has a fifty day moving average price of $149.73 and a two-hundred day moving average price of $153.19.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.71 by $0.11. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The business had revenue of $22.45 billion during the quarter, compared to analyst estimates of $22.33 billion. During the same period in the prior year, the company posted $2.80 EPS. The business’s revenue for the quarter was up 4.3% compared to the same quarter last year. On average, equities research analysts forecast that Johnson & Johnson will post 10.07 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th will be given a $1.24 dividend. The ex-dividend date is Tuesday, August 27th. This represents a $4.96 dividend on an annualized basis and a yield of 3.02%. Johnson & Johnson’s dividend payout ratio is presently 30.92%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.